Compare Merck & Co., Inc. (MRK) vs NICE Ltd (NICE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs NICE Ltd — how do they compare? Merck & Co., Inc. trades at $148.24 (market cap $366.28B), while NICE Ltd trades at $98.12 (market cap $5.94B). The key difference: Merck & Co., Inc. is far larger — about 61.7× NICE Ltd's market cap, and Merck & Co., Inc. pays a 2.29% dividend while NICE Ltd pays none. Which is the better fit depends on your goals.
| MRK | NICE | |
|---|---|---|
Market Cap | $366.28B | $5.94B |
Sector | Health | Technology |
52-Week High | $156.43 | $153.44 |
52-Week Low | $77.60 | $83.15 |
Enterprise Value | $413.04B | $5.67B |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
NICE stock trades at $101.47, down 3.82% in the last session, reflecting near-term bearish technical signals. The company maintains strong fundamentals with a P/E of 14.77 and robust profitability, including a 65.12% gross margin and consistent earnings beats in recent quarters. Recent news highlights AI platform deployments with major clients like AOK PLUS and Bluecrest, reinforcing growth in the CX segment. Analyst consensus remains positive with a $118.67 price target, though technical indicators suggest caution amid a bearish overall signal.
The outlook for NICE is supported by solid cloud and AI revenue growth, upward EPS guidance, and a debt-light balance sheet. Key risks include execution challenges in scaling AI offerings and competitive pressures in the customer engagement software market. With no sell ratings from analysts and institutional accumulation, the stock presents a value opportunity for long-term investors despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →
